Unlike current treatments on the market for hereditary angioedema, navenibart requires dosing only every 3-6 months.

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom ...

Among adults with hereditary angioedema, the safety of navenibart up to 24 months was favorable, according to interim trial ...

Kalbitor (ecallantide) is a medicine used to treat sudden attacks of hereditary angioedema (HAE). During an HAE attack, swelling happens in different areas of the body, such as your face, hands, feet, ...

Angioedema without wheals (AE) is a distinct clinical condition characterized by self-limiting and localized edema that occurs without the presence of urticaria. This condition manifests as swelling ...

Among 100 surveyed U.S. patients with HAE, 89% of whom were on long-term prophylaxis therapies and 11% of whom were on on-demand therapies only, 34% reported having at least one attack per month and ...

Please provide your email address to receive an email when new articles are posted on . The mean attack rate at baseline was 2.18, and this dropped to 0.12 in the open-label extension study. There was ...

(BPT) - In the U.S., about 7,000 people live with hereditary angioedema, or HAE, 1,2 a rare condition that results in unpredictable swelling attacks. 3-8 Symptoms often appear early in life and can ...

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary ...